Form 4: Protagonist Therapeutics Director Waddill Exercises Options and Sells Shares

Director William D. Waddill exercised stock options and sold shares of Protagonist Therapeutics, Inc. on March 1, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 1, 2024, William D. Waddill, a director of Protagonist Therapeutics, Inc., exercised stock options to acquire 12,975 shares of common stock at a price of $6.09 per share.
• Simultaneously, Waddill sold 12,975 shares of common stock at a weighted average price of $31.34 per share, with individual sales ranging from $30.46 to $31.99.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2023.
• Following these transactions, Waddill directly owns 12,000 shares of Protagonist Therapeutics.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were pre-planned under a 10b5-1 trading plan. The director exercised options and sold shares, which is a common practice.

Positives

• The exercise of stock options at $6.09 indicates a previous belief in the company's potential.
• The sale price of $31.34 is significantly higher than the exercise price, resulting in a profit for the director.

Negatives

• The sale of shares by a director could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• The market's reaction to the director's sale could potentially impact the stock price in the short term.
• Continued sales by insiders, even under 10b5-1 plans, could create downward pressure on the stock.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are common in the pharmaceutical industry. Monitoring these transactions can provide insights into management's perspective on the company's prospects, but should be considered in the context of pre-arranged trading plans.

Comparison to Industry Standards

• Comparing the director's trading activity to similar transactions by insiders at comparable biotech companies (e.g., companies with similar market capitalization and pipeline stage) could provide a benchmark for assessing the significance of this event.
• For example, if other directors at peer companies are also selling shares under 10b5-1 plans, it might suggest a broader trend related to personal financial planning rather than company-specific concerns.
• Conversely, if insider buying is more prevalent among peers, it could raise questions about the relative attractiveness of Protagonist Therapeutics' stock.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholder sentiment in the short term.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates